Credit: Original article published here.
Galit Zuckerman-Stark, Founder and CEO of Medasense Biometrics, spoke with DocWire about the company’s Nociception Level Index (NOL) technology, a measure of peri-operative pain, and its potential to improve surgery outcomes.
NOL technology is currently being used in several countries across the globe, and the US Food and Drug Administration recently granted marketing authorization for the NOL monitoring platform through the de novo premarket approval pathway.
View More Interviews With a Variety of Specialists
